the aid library

LIST OPTIONS

Filter

2645

Sort by:

Direction:

Download (602)

View PDF (1056)

Cervical Cancer Prevention and Control Policy (South Africa)

Dept. of Health, Republic of South Africa (2021) C1

Cervical cancer, along with maternal deaths, has been identified as a national priority in South Africa as well as other Sub-Saharan African countries. Cervical cancer is the second most common cancer among women in South Africa, after breast cancer. Due to limited access to prevention, early dia... more

Download (160)

View PDF (217)

Global spending on health: rising to the pandemic’s challenges

World Health Organization WHO (2022) C_WHO

The results of the report clearly show that in 2020, a year dominated by the emergence of COVID-19 and its associated health and economic crises, governments around the world rose to the challenge. Sharp increases in government spending on health at all country income levels underpinned the rise in ... more

Download (94)

View PDF (96)

Audited Financial Statements for the year ended 31 December 2020

World Health Organization (WHO) World Health Organization (WHO) (2021) CC

WHO’s total revenue in 2020 was US$ 4299 million and total expenses were US$ 3561 million, resulting in a surplus of US$ 824 million, which includes finance revenue (e.g. interest and investment income) of US$ 86 million, representing increases of 38% and 15% in revenue and expenses respectively. ... more

Download (110)

View PDF (110)

Working Paper 46 - Aid, China, and Growth: Evidence from a New Global Development Finance Dataset

Dreher, A.; A. Fuchs; B. Parks et al. AidData at William & Mary (2017) CC

This paper introduces a new dataset of official financing—including foreign aid and other forms of concessional and non-concessional state financing—from China to 138 countries between 2000 and 2014. We use these data to investigate whether and to what extent Chinese aid affects economic growth ... more

Download (115)

View PDF (137)

Are donors targeting the greatest health needs? Evidence from mining sites in the D.R.Congo

S. Lordemus AidData at William & Mary (2019) CC

I examine the effectiveness of donors in targeting the highest burden of malaria in the Democratic Republic of Congo when health information structure is fragmented. I exploit local variations in the burden of malaria induced by mining activities as well as financial and epidemiological data from he... more

Download (142)

View PDF (153)

Financing the SDGs: Evidence in Four Countries

Jennifer Turner AidData at William & Mary (2019) CC

Achieving the Sustainable Development Goals (SDGs) will require the international community to mobilize significant additional financing over the next decade. Tracking and analyzing this funding is central to measuring progress and making more informed choices to direct financial flows where they wi... more

Download (96)

View PDF (345)

Assessing development assistance for child survival between 2000 and 2014: A multisectoral perspective

Lu, C.; A. Chu, Z. Li et al. PLOS One (2017) CC

The majority of Countdown countries did not reach the fourth Millennium Development Goal (MDG 4) on reducing child mortality, despite the fact that donor funding to the health sector has drastically increased. When tracking aid invested in child survival, previous studies have exclusively focused on... more

Download (93)

View PDF (86)

Sustainable financing: Report by the Director-General

World Health Organization (WHO) World Health Organization (WHO) (2021) CC

The biennium 2020–2021 has revealed more clearly than ever the need for a strong, credible and independent WHO on the world stage. The coronavirus disease (COVID-19) crisis has demonstrated the fundamental importance of the global detection, response and coordination roles that only WHO can play a... more

Download (92)

View PDF (149)

Countdown to 2015: an analysis of donor funding for prenatal and neonatal health, 2003–2013

Pitt, C.; C. Grollman; M. Martínez-Álvarez et al. BMJ Global Health (2017) C1

Background: In 2015, 5.3 million babies died in the third trimester of pregnancy and first month following birth. Progress in reducing neonatal mortality and stillbirth rates has lagged behind the substantial progress in reducing postneonatal and maternal mortality rates. The benefits to prenatal an... more

Download (300)

View PDF (114)

Financing Global Health 2015: Development assistance steady on the path to new Global Goals

Institute for Health Metrics and Evaluation (2016) CC

Financing Global Health 2015 is the seventh edition of IHME’s annual series on global health financing. This report captures trends in development assistance for health (DAH) and government health expenditure as source (GHE-S) in low- and middle-income countries. Annually updated GHE-S and DAH est... more

Download (109)

View PDF (114)

Tracking aid for global health goals: a systematic comparison of four approaches applied to reproductive, maternal, newborn, and child health

Pitt C.; Grollman C.; Martinez-Alvarez M. et al The Lancet (2018) CC

Four initiatives have estimated the value of aid for reproductive, maternal, newborn, and child health (RMNCH): Countdown to 2015, the Institute for Health Metrics and Evaluation (IHME), the Muskoka Initiative, and the Organisation for Economic Co-operation and Development (OECD) policy marker. We... more

Download (77)

View PDF (110)

Tracking official development assistance for reproductive health in conflict-affected countries: 2002—2011

Patel P.; Dahab M.; Tanabe M. et al. BJOG An International Journal of Obstetics and Gynaecology (2016) CC

To provide information on trends on official development assistance (ODA) disbursement patterns for reproductive health activities in 18 conflict-affected countries

Download (92)

View PDF (111)

Tracking Official Development Assistance for Reproductive Health in Conflict-Affected Countries

Patel P.; Roberts B.; Gury S. et al. PLOS Medecine (2009) CC

Reproductive health needs are particularly acute in countries affected by armed conflict. Reliable information on aid investment for reproductive health in these countries is essential for improving the efficiency and effectiveness of aid. The purpose of this study was to analyse official developm... more

Download (115)

View PDF (114)

WHO Guide to conducting programme reviews for HIV, viral hepatitis and sexually transmitted infections

World Health Organization WHO (2023) C_WHO

Sound periodic programme reviews provide opportunities for countries to objectively assess progress and take corrective action to sustain or get back on track towards achieving their medium and long-term programme goals. It reflects people’s diverse needs, enables efficient use of health system re... more

Download (176)

View PDF (153)

Policy brief on tuberculosis-associated disability

World Health Organization WHO (2023) C_WHO

People affected by impairments and disabilities associated with TB are even more likely to belong to marginalized segments of society and are more likely to have their human rights unprotected. The challenges faced by people affected by TB include the consequences of impairment and disability associ... more

Download (245)

View PDF (330)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (115)

View PDF (86)

Closing the SDG budget gap

Move Humanity (2018) CC

This report shows that increased domestic revenues can and will cover only part of the necessary SDG budget spending of the LIDCs. Achieving the SDGs in the LIDCs will also require increases of both Official Development Assistance (ODA) and Private Development Assistance (PDA) to reach aggregate lev... more

Download (198)

View PDF (97)

Analysis of Pandemic Preparedness and Response (PPR) architecture, financing needs, gaps and mechanisms

World Bank (2022) CC

A global Pandemic, Preparedness and Response (RRR) architecture

Download (135)

View PDF (281)

Guidelines for drinking-water quality: Small water supplies

World Health Organization WHO (2024) C_WHO

Small drinking-water supplies commonly experience operational, managerial, technical and resourcing challenges that impact their ability to deliver safe and reliable services. The needs and opportunities associated with these supplies therefore warrant explicit consideration in policies and regulati... more

Download (130)

View PDF (268)

Guidelines for drinking-water quality: small water supplies - Executive summary

World Health Organization WHO (2024) C_WHO

The Guidelines for drinking-water quality: small water supplies have been developed to address the needs and opportunities associated with small supplies to facilitate progressive improvement towards safe and sustainable drinking-water services for all. These Guidelines are based on the principal re... more